TY  - JOUR

T1  - Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England

JO  - Drugs - Real World Outcomes

UR  - http://dx.doi.org/10.1007/s40801-023-00415-w

PY  - 2024/01/24

AU  - Brown J

AU  - Harrow B

AU  - Marciniak A

AU  - McCarthy C

AU  - Houchard A

AU  - Cirneanu L

AU  - Protheroe A

ED  - 

DO  - DOI: 10.1007/s40801-023-00415-w

PB  - Springer Science and Business Media LLC

Y2  - 2024/12/22

ER  -